IDEAYA Biosciences receives $210mln upfront for darovasertib license, up to $320mln in milestones.

• Servier and IDEAYA Biosciences enter exclusive license agreement for darovasertib. • Darovasertib is a small molecule for uveal melanoma, a rare eye cancer. • IDEAYA to receive $210 million upfront and up to $320 million in milestones. • Double-digit royalties on net sales. • Companies to collaborate on development and share costs.

Servier and IDEAYA Biosciences have entered into an exclusive license agreement to bring darovasertib, a promising treatment for uveal melanoma, to patients worldwide. Darovasertib, a small molecule developed by IDEAYA, is designed to address the significant unmet medical need for uveal melanoma, a rare and aggressive form of eye cancer [1].

Under the agreement, Servier will obtain the regulatory and commercial rights for darovasertib in all territories outside the United States, while IDEAYA retains its rights for darovasertib in the U.S. IDEAYA will receive an upfront payment of $210 million and up to $320 million in regulatory and commercial milestones, plus double-digit royalties on net sales. The companies will collaborate on the development of darovasertib and share the associated costs [1].

Darovasertib has received US FDA Breakthrough Therapy Designation and Fast Track designation for its potential use in neoadjuvant and metastatic uveal melanoma, respectively. It has also been designated as an Orphan Drug by the US FDA. The treatment is currently being evaluated in multiple global clinical trials, including Phase 2/3 and Phase 3 trials [1].

Servier, an independent international pharmaceutical company, is committed to delivering transformative therapies to patients with significant medical needs. With a strong focus on oncology, Servier has expanded its portfolio to include precision medicine therapies. IDEAYA Biosciences, a precision medicine oncology company, specializes in the discovery, development, and commercialization of targeted therapies for cancer [1].

The collaboration between Servier and IDEAYA Biosciences aims to accelerate the global development of darovasertib across three Phase 3 registrational trials, targeting patient outcomes in neoadjuvant, adjuvant, and metastatic settings. The companies are optimistic that the partnership will ensure that this potentially life-changing treatment reaches as many patients as possible [1].

References:
[1] https://www.prnewswire.com/news-releases/servier-and-ideaya-biosciences-partner-to-bring-darovasertib-a-promising-uveal-melanoma-treatment-to-patients-worldwide-302543276.html